There is a recognised need to develop insulin products with faster onset of action compared with the current state-of-the-art prandial insulin products. Prandial insulin is used by diabetics to control the blood glucose rise after meals. To ensure effective blood glucose management it is essential that, once injected, insulin begins to act as rapidly as possible. Whilst there has been good progress in developing rapid acting insulins in the last two decades, there is a strong need to develop products that are even more rapid-acting to ensure lower variability of post-meal blood glucose elevations and lower rates of hypoglycaemia. Ultra-rapid acting insulin is also a key component required for the development of efficient closed-loop pump systems that would enable automatic glucose control based on a combination of continuous glucose measurement, smart algorithms to decide how much insulin ultra-rapid acting insulin to deliver via an insulin pump. The rapidity of response is critical in such systems in order to minimise spikes outside the required glucose levels. Ultra-rapid acting insulin will deliver to patients a more effective tool to manage their diabetes, particularly around meal-times, which will result in improved quality of life and health outcomes for people living with diabetes.
Arecor’s ultra-rapid acting insulin product has a pharmacokinetic profile that has a considerably more rapid onset compared with currently marketed rapid acting insulins. Arecor has achieved such ultra-rapid onset by applying its proprietary formulation technology to existing insulin products. The unique formulation combines excipients that both accelerate the onset of action and that ensure the required product stability.
Arecor has completed the formulation development, demonstrating ultra-rapid onset in a validated diabetic pig model as well as excellent stability profile. The first human clinical trials are planned for 2018.
Arecor is developing an ultra-rapid acting insulin that more closely matches a healthy body’s physiological response to blood glucose, which will be a major advancement for diabetes care. Even faster acting insulins should lead to better postprandial glycaemic control, reduction in variability, improved HbA1c and allow greater flexibility in the timing of insulin injections.